RecruitingPhase 2NCT07384416
Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer
Studying Malignant tumor of penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Intervention
- QL1706 + Lenvatinib + Nab-Paclitaxel(drug)
- Enrollment
- 47 enrolled
- Eligibility
- 18-80 years · MALE
- Timeline
- 2026 – 2031
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07384416 on ClinicalTrials.govOther trials for Malignant tumor of penis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07378670DEfeating PEnile CAncer-2University Hospital Tuebingen
- RECRUITINGPHASE2NCT07110038DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGPHASE1NCT07054307MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell CarcinomaJiyan Liu
- RECRUITINGPHASE2NCT06353906Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT06465914A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesShanghai Bovax Biotechnology Co., Ltd.
- ENROLLING BY INVITATIONNCT06565585Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell CarcinomaUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06415318TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile CancerSun Yat-sen University
- RECRUITINGPHASE1NCT05999396FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal CancerGerman Cancer Research Center